L-arginine plasma levels and severity of idiopathic pulmonary arterial hypertension

Vasa - Journal of Vascular Diseases

Volumn 37, Issue 1, 2008, Pages 61-67

  Beyer, J ^a   Kolditz, M ^a   Ewert, R ^b   Rubens, C ^d   Opitz, C ^c   Schellong, S ^a   Hoeffken, G ^a   Halank, M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c DRK KLINIKEN BERLIN WESTEND   (Germany)

^d Hanse Klinikum Stralsund   (Germany)

Author keywords

Cardiopulmonary hemodynamics; Idiopathic pulmonary arterial hypertension; L arginine; Six minute walk distance

Indexed keywords

ARGININE; CITRULLINE; HYDROXYL GROUP; NITRIC OXIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; HEART CATHETERIZATION; HEART INDEX; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IDIOPATHIC DISEASE; LUNG CAPILLARY PRESSURE; MALE; OXYGEN SATURATION; PATHOGENESIS; PROGNOSIS; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SYSTEMIC VASCULAR RESISTANCE; VASCULAR RESISTANCE; VASODILATATION;

ADULT; AGED; ARGININE; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRULLINE; COHORT STUDIES; EXERCISE TEST; FEMALE; HEART CATHETERIZATION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PILOT PROJECTS; PULMONARY ARTERY; SEVERITY OF ILLNESS INDEX;

EID: 40349098047     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.37.1.61     Document Type: Article

References (29)

1. Arnal JF, Munzel T, Venema R, James N, Bai C, Mitch W, et al. Interactions between L-arginine and L-glutamine change endothelial NO production: an effect independent of NO synthase substrate availability. J Clin Invest 1995; 95: 2565-72.
2. ATS-Statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-7.
3. Black SM, Fineman JR. Oxidative and nitrosative stress in pediatric pulmonary hypertension: roles of endothelin-1 and nitric oxide. Vascul Pharmacol 2006; 45: 308-16.
4. Böger RH, Mugge A, Bode-Böger SM, Heinzel D, Höper MM, Frölich JC. Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension. Int J Clin Pharmacol Ther 1996; 34: 323-8.
5. Bolotina VM, Najibi S, Palacino JJ, Pagano P, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994; 368: 850-3.
6. Frostell CG, Zapol WM. Inhaled nitric oxide and related nitric oxide donors in the lung: a trans-atlantic review. In: Feelisch M, Stamler JS, ed. Methods in nitric oxide research. John Wiley and Sons Ltd, 1996; 645-59.
7. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352: 719-25.
8. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7.
9. Garlichs CD, Beyer J, Zhang H, Schmeisser A, Plötze K, Mügge A, et al. Decreased plasma concentrations of L-hydroxy-arginine as a marker of reduced NO formation in patients with combined cardiovascular risk factors. J Lab Clin Med 2000; 135: 419-25.
10. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, Hoeper MM. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005; 25: 1414-8.
11. Kurz S, Harrison D. Insulin and the arginine paradox. J Clin Invest 1997; 99: 369-70.
12. Mc Goon MD. Prognosis and natural history. In: Rubin LJ, Rich S, eds. Primary pulmonary hypertension. New York, NY: Marcel Dekker, 1997; 305-17.
13. Michel T, Feron O. Nitric oxide synthases : which, where, how, and why? J Clin Invest 1998; 100: 2146-52.
14. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of the six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-92.
15. Morris CR, Morris SM, Hagar W, van Warmerdam J, Claster S, Kepka-Lenhart D, et al. Arginine Therapy: A new treatment of pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003; 168: 63-9.
16. Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, Kyotani S, et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Resir Crit Care Med 2001; 163: 887-91.
17. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Kleptko W, et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 2005; 19: 1175-7.
18. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-23.
19. Rich S, Levy PS. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. Am J Med 1984; 76: 573-8.
20. Robertson BE, Schubert R, Hescheler J, Nelson MT. C-GMP-dependent protein kinase activates Ca-activated K+ channels in cerebral artery smooth muscle cells. Am J Physiol (Cell Physiol) 1993; 265: C299-C303.
21. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, et al. Big Endothelin-1 and Endothelin-1 Plasma Levels are correlated wit the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-9.
22. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7.
23. Sharma RV, Tan E, Fang S, Gurjar MV, Bhalla RC. NOS gene transfer inhibits expression of cell cycle regulatory molecules in vascular smooth muscle cells. Am J Physiol 1999; 276: H1450-H1459.
24. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-Term Intravenous Epoprostenol Infusion in Primary Pulmonary Hypertension. J Am Coll Cardiol 2002; 40: 780-8.
25. Souza-Costa DC, Zerbini T, Metzger IF, Rocha JB, Gerlach RF, Tanus-Santos JE. 1-Arginine attenuates acute pulmonary embolism-induced oxidative stress and pulmonary hypertension. Nitric Oxide 2005; 12: 9-14.
26. Stuehr DJ, Kwon KS, Nathan CF, Griffith OW, Feldman PL, Wiseman J. N omega-hydroxy-L-arginine- is an intermediate in the biosynthesis of nitric oxide from L-arginine. J Biol Chem 1991; 266: 6259-63.
27. Surdacki A, Zmudka K, Bieron K, Kostka-Trabka E, Dubiel JS, Dubiel JS, et al. Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension. Wien Klin Wochenschr 1994; 106: 521-6.
28. Xu W, Kaneko T, Zheng S, Comhair SA, Janocha AJ, Goggans T, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004; 18:1746-8.
29. Zhou HL and Torphy TJ. Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators. J Pharmacol Exp Ther 1991; 258: 972-8.